Novartis, Armed With New IP, Again Sues Over $3B MS Drug

Law360 (January 29, 2020, 3:23 PM EST) -- Immediately after Novartis was granted a new patent Tuesday, the pharma giant sued a large group of generic-drug makers hoping to block their competing versions of its $3 billion multiple sclerosis drug Gilenya.

Novartis Pharmaceuticals Corp.'s suit, filed Tuesday in Delaware federal court, is trying to block Apotex Inc., Glenmark Pharmaceuticals, Zydus Pharmaceuticals and others from making and selling generic versions of Gilenya until the new patent expires in December 2027. 

The suit also names BionPharma Inc., a startup created by former Ranbaxy Laboratories executives; Heritage Pharmaceuticals, now renamed Avet Pharma, and its parent, Emcure Pharmaceuticals; Ezra Pharma; HEC Pharm; Hetero...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!